Skip to main content
Caplight Logo









STALICLA

STALICLA

Private
GenevaHealthcare & Life Scienceshttps://stalicla.com/

Last Round

VC Round

Jun 30, 2025

Total Funding Raised

$49.86M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

STALICLA is a biopharmaceutical company that develops precision medicine for neurodevelopmental and neuropsychiatric disorders using its proprietary DEPI platform.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Precision Medicine, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

precision medicinedrug discoverypatient stratificationbiotechmulti-omicsneurodevelopmental disordersAI drug discoveryin silico drug discoverysmall moleculecomputational biologyclinical-stage biotechAI-driven medicinebiopharmadrug repurposingneuropsychiatric disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

STALICLA Comparables

Compare STALICLA with similar companies based on industry and business-model similarity.

STALICLA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alto Neuroscience
77%
Itay & Beyond
76%
Insilico Medicine
76%

STALICLA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 30, 2025
Series BJan 16, 2024
Series AFeb 3, 2020
SeedJun 30, 2018

Key People

Founding team and executive leadership

Lynn Durham

CEO and Founder

Founding Team

Laurent Forestier

Group CFO

Executive Team

Amazon Austin

Chief Operating Officer

Executive Team

STALICLA Investors

Notable investors and investment history

STALICLA investors
InvestorRounds
4see venturesSeries A
Akilia PartnersSeed, Series B, Series A
SPRIM Global InvestmentsSeries B
Forestay CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors increased 52% MoM.

  • Feb 7, 2026

    Grew 19% QoQ, from 21 to 25 employees.

STALICLA Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

STALICLA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about STALICLA's valuation, stock price, and market status.

Firmographic Details

HeadquartersGeneva
Employee Range17
Year Founded2017
Last FundingJun 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?